117 related articles for article (PubMed ID: 28375629)
1. Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.
Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock I; Sahasrabudhe P; Bonin P; Hay DA; Brennan PE; Pletcher M; Jones LH; Chekler ELP
J Med Chem; 2017 Jul; 60(13):5349-5363. PubMed ID: 28375629
[TBL] [Abstract][Full Text] [Related]
2. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
4. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
[TBL] [Abstract][Full Text] [Related]
7. Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
Ji Z; Clark RF; Bhat V; Matthew Hansen T; Lasko LM; Bromberg KD; Manaves V; Algire M; Martin R; Qiu W; Torrent M; Jakob CG; Liu H; Cole PA; Marmorstein R; Kesicki EA; Lai A; Michaelides MR
Bioorg Med Chem Lett; 2021 May; 39():127854. PubMed ID: 33631370
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
9. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
[TBL] [Abstract][Full Text] [Related]
11. Development of Dimethylisoxazole-Attached Imidazo[1,2-
Muthengi A; Wimalasena VK; Yosief HO; Bikowitz MJ; Sigua LH; Wang T; Li D; Gaieb Z; Dhawan G; Liu S; Erickson J; Amaro RE; Schönbrunn E; Qi J; Zhang W
J Med Chem; 2021 May; 64(9):5787-5801. PubMed ID: 33872011
[TBL] [Abstract][Full Text] [Related]
12. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 8-Methyl-pyrrolo[1,2-
Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
[TBL] [Abstract][Full Text] [Related]
14. Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors.
Mitra S; Dash R
J Mol Graph Model; 2018 Aug; 83():42-52. PubMed ID: 29758466
[TBL] [Abstract][Full Text] [Related]
15. Selective Fragments for the CREBBP Bromodomain Identified from an Encoded Self-assembly Chemical Library.
Catalano M; Moroglu M; Balbi P; Mazzieri F; Clayton J; Andrews KH; Bigatti M; Scheuermann J; Conway SJ; Neri D
ChemMedChem; 2020 Sep; 15(18):1752-1756. PubMed ID: 32686307
[TBL] [Abstract][Full Text] [Related]
16. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
17. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities.
Chekler EL; Pellegrino JA; Lanz TA; Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock IA; Sahasrabudhe P; Bonin PD; Lee K; Pletcher MT; Jones LH
Chem Biol; 2015 Dec; 22(12):1588-96. PubMed ID: 26670081
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors.
Xu W; Gray DL; Glase SA; Barta NS
Bioorg Med Chem Lett; 2008 Oct; 18(20):5550-3. PubMed ID: 18805691
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.
Wei J; Yang Y; Lu M; Lei Y; Xu L; Jiang Z; Xu X; Guo X; Zhang X; Sun H; You Q
Mini Rev Med Chem; 2018; 18(4):296-309. PubMed ID: 27484627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
